WELIREG®▼ (belzutifan) Efficacy & Safety
Prescribing Information [External link]
Understand more behind the unmet need in VHL and the value of WELIREG. Explore the efficacy and safety data and learn about treatment and adverse event management.
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.
For more information on WELIREG visit the product page:
